Artiva (ARTV) CEO Aslan Fred Receives Award

What Happened Aslan Fred, CEO of Artiva Biotherapeutics (ARTV), was granted a total of 425,000 equity awards on September 15, 2026. The filing shows a grant of 110,000 shares (restricted stock units) and an additional 315,000 shares classified as derivative/award units. Both grants were recorded at $0.00 per share (no cash paid at grant).

These are awards (not open-market purchases or sales), which are typically compensation/retention tools rather than immediate market bets. The awards will vest over time per the plan terms noted in the filing.

Key Details

• Transaction date: 2026-09-15 (filed same day; Accession: 0001193125-26-392025).
• Grants: 110,000 shares (RSU) and 315,000 shares (derivative award); price recorded $0.00; total cash consideration $0.
• Footnotes:
  • F1: The award is a restricted stock unit (RSU) granted under the Issuer's 2024 Equity Incentive Plan.
  • F2: Vesting schedule begins Sept 8, 2026 — 1/48th of the shares subject to the option/award vest in equal monthly installments over four years.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Filing and transaction date match (no late filing indicated in the provided data).

Context RSU and similar derivative awards are compensation and usually vest over a multi-year schedule; they do not involve immediate cash outlay and do not necessarily signal buying/selling intent. The $0.00 grant price simply reflects that shares were awarded rather than purchased. Taxable events (and any subsequent sales) would generally occur as awards vest or are settled.